Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus

2013 ◽  
Vol 29 (12) ◽  
pp. 1587-1597 ◽  
Author(s):  
Beth D. Mitchell ◽  
Elizabeth L. Eby ◽  
Maureen J. Lage
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic

DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents

2016 ◽  
Vol 13 (4) ◽  
Author(s):  
Askandar Tjokroprawiro ◽  
Sri Murtiwi ◽  
Raymond R. Tjandrawinata
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Prospective Clinical Study ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic ◽  
Enhance Insulin Sensitivity ◽  
Bioactive Fraction

AbstractBackgroundDLBS3233, a combined bioactive fraction ofMethodsThis was an open and prospective clinical study for 12 weeks of therapy, involving type-2 diabetes mellitus patients who had been treated with two oral antidiabetic agents for at least 3 months prior to screening, yet, with HbAResultsAfter 12 weeks of treatment, the HbAConclusionsThe add-on oral antidiabetes therapy with DLBS3233 at the dose of 100 mg once daily helped type-2 diabetes mellitus patients to improve their glycemic control, enhance insulin sensitivity, lipid profile, and adiponectin level. In addition, DLBS3233 treatment concomitantly with other oral antidiabetic agents was proven safe and tolerable in type-2 diabetes subjects.

Oral Antidiabetic Agents: A Comparative Review

2004 ◽  
Vol 17 (1) ◽  
pp. 39-48 ◽  
Author(s):  
Renee R. Koski
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
The United States ◽  
Oral Antidiabetic Agents ◽  
Antidiabetic Agents ◽  
Oral Antidiabetic ◽  
Oral Agents ◽  
Comparative Review

Type 2 diabetes mellitus is a chronic disease characterized by insulin resistance, impaired insulin secretion, and/or increased hepatic glucose production. The mainstays of drug treatment are the oral antidiabetic agents. Insulin is usually reserved for patients who do not achieve fasting plasma glucose or A1C goals with or cannot tolerate the oral antidiabetic agents. There are 5 classes of oral antidiabetic agents available in the United States: sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and nonsulfonylurea secretagogues. They have differences and similarities with respect to their pharmacology and role in diabetes. This article reviews the pharmacology, efficacy, safety, and selection of the oral agents used to treat type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document